1. Show article details.

    PRESS DIGEST- New York Times business news - May 26

    Reuters – 12:33 AM ET 05/26/2015

    The following are the top stories on the New York Times business pages. * Charter Communications Inc (CHTR) is close to buying Time Warner Cable Inc (TWC), and a deal could be announced as soon as Tuesday, people close to the talks said.

  2. Show article details.

    China Diabetes Management Devices Market Growth to be Driven by Rise in Sedentary Lifestyle and Life Expectancy and Patient Compliant Technologies Especially for Insulin Pump and CGM

    PR Newswire – 10:40 AM ET 05/20/2015

    LONDON and NEW YORK, May 20, 2015 China, with 100 million diabetics has already outpaced other nations in terms of number of diabetics.

  3. Show article details.

    Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease

    PR Newswire – 8:00 AM ET 05/19/2015

    PARIS, May 19, 2015 Abbott announced today that it has received CE Mark for the latest advancement of its Absorb stent system, called Absorb GT1™, which combines the world's first fully dissolving stent with a next-generation delivery catheter to help doctors treat people with heart disease.

  4. Show article details.

    Credits & Debits

    DJ Business News – 8:30 PM ET 05/18/2015

    Statoil ASA (STO), a Norwegian oil producer, transporter and refiner, appointed Hans Jakob Hegge chief financial officer, effective Aug. 1. Mr. Hegge is a senior vice president focused on operations in the Norwegian Sea and Barents Sea. He will succeed Torgrim Reitan.

  5. Show article details.

    How a drink for babies became the adult hangover cure of choice

    MarketWatch – 11:02 AM ET 05/17/2015

    Pedialyte, that perennially popular oral electrolyte for ailing kids, has a new target consumer in mind. Adult usage of the brand, owned by Similac formula parent Abbott Laboratories (ABT), has grown by almost 60% since 2012. Adults now make up more than one-third of Pedialyte's sales, up from a historical average of 10% to 15%, Heather Mason, an executive vice president at Abbott, said in an interview. The Pedialyte brand doesn't disclose its actual sales, but Nielsen tracking shows retail...

  6. Show article details.

    The 10 biggest business stories this week

    MarketWatch – 1:29 PM ET 05/15/2015

    An interesting tech merger, oil-stock picks and the conflict between bulls and bears led the news. MarketWatch rounded up the 10 most important news events of the past week. We focused on market-related issues, but we've included other subjects of interest to readers.

  7. Show article details.

    AstraZeneca digs into precision medicine with lung, heart deals

    Reuters – 7:01 PM ET 05/12/2015

    * Drugmaker taking personalised healthcare beyond cancer. * Deal with Abbott to develop diagnostic for asthma drug. * Tie-up with Montreal scientists on heart disease genes. By Ben Hirschler. AstraZeneca (AZN) is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease.

  8. Show article details.

    India Coronary Stent Market to be Tripled by 2021

    PR Newswire – 4:24 AM ET 05/05/2015

    LONDON, May 5, 2015 - No one has covered cath labs in India like us: ABMRG. - Primary research covering 700 angioplasty centres in 150 cities.

  9. Show article details.

    Abbott's First-of-its-Kind Blood Test to Aid in Detecting Early Pregnancy Could Help Doctors Make Faster Treatment Decisions for Women

    PR Newswire – 9:00 AM ET 04/30/2015

    ABBOTT PARK, Ill., April 30, 2015Women account for nearly 60 percent of visits to emergency departments in the United States.1 In emergency situations, it is critical for doctors to know the pregnancy status of women who are of childbearing age as soon as possible, since this influences decision-making when it comes to medications, imaging, surgery and other clinical care.

  10. Show article details.

    Makers of Baby Formula Press Their Case on WIC Program

    DJ Business News – 7:51 PM ET 04/27/2015

    Capitol Hill lawmakers will soon be wrestling over the future of one of the nation's biggest food-assistance programs, and the makers of infant formula are among the unlikely players in the middle of the scrum. The law authorizing the $6 billion-a-year WIC program, which provides food vouchers to pregnant or postpartum women and their young children, is up for renewal this year. One of the largest formula makers has suggested the program's eligibility should be tightened,...

  11. Show article details.

    The Rise of the 'Stichting,' an Obscure Takeover Defense

    DJ Business News – 12:30 PM ET 04/22/2015

    LONDON--A centuries-old Dutch legal structure that has become a popular self-defense tool for companies and wealthy individuals could play a leading role in a takeover battle now shaping up. Israel's Teva Pharmaceutical Industries Ltd. (TEVA) said Tuesday it is bidding $40 billion for Mylan NV (MYL), a drug company with headquarters in Canonsburg, Pa., but incorporated in the Netherlands. In early April, moving preemptively to thwart such an offer, a Dutch law firm submitted paperwork on...

  12. Show article details.

    Abbott says its payoff from Mylan deal surged

    Reuters – 12:09 PM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

  13. Show article details.

    Abbott says payoff from Mylan deal surges, as Mylan shares leap

    Reuters – 10:53 AM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

  14. Show article details.

    Abbott Labs Reports Better-Than-Expected Profit

    DJ Business News – 9:55 AM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its first-quarter earnings rose, thanks largely to a gain stemming from recent divestitures, although currency fluctuations weighed on sales growth. The company said the stronger dollar shaved 7% from its top line. The Illinois-based health-care company has been realigning its business in a series of deals.

  15. Show article details.

    Abbott Labs Reports Better-Than-Expected Profit -- Update

    DJ Business News – 9:31 AM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its first-quarter earnings rose, thanks largely to a gain stemming from recent divestitures, although currency fluctuations weighed on sales growth. The company said the stronger dollar shaved 7% from its top line. The Illinois-based health-care company has been realigning its business in a series of deals.

  16. Show article details.

    Abbott Labs Reports Better-Than-Expected Profit

    DJ Business News – 9:22 AM ET 04/22/2015

    Abbott Laboratories (ABT) on Wednesday said its first-quarter earnings rose, thanks largely to a gain stemming from recent divestitures, although currency fluctuations weighed on sales growth. The company said the stronger dollar shaved 7% from its top line. The Illinois-based health-care company has been realigning its business in a series of deals.

  17. Show article details.

    Abbott profit beats expectations, sales of branded generics jump

    Reuters – 9:09 AM ET 04/22/2015

    Abbott Laboratories (ABT) reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions. Sales in the company's division that sells branded generic drugs in emerging markets, jumped 31.8 percent in the first quarter even after including the impact of the strong dollar.

  18. Show article details.

    Abbott Labs profit from continuing operations more than doubles

    Reuters – 8:05 AM ET 04/22/2015

    Abbott Laboratories' (ABT) net earnings from continuing operations more than doubled in the first quarter, with strong performance in its branded generics, international nutrition and diagnostics divisions. The company's net earnings from continuing operations jumped to $529 million, or 35 cents per share, in the quarter ended March 31, from $224 million, or 14 cents per share, a year earlier.

  19. Show article details.

    Abbott Reports First-Quarter 2015 Results

    PR Newswire – 7:45 AM ET 04/22/2015

    ABBOTT PARK, Ill., April 22, 2015 Abbott today announced financial results for the first quarter ended March 31, 2015. "We're off to a good start this year, with particularly strong performance in our branded generics, international nutrition and global diagnostics businesses," said Miles D. White, chairman and chief executive officer, Abbott.

  20. Show article details.

    Mylan Is Too Big a Pill for Teva

    MarketWatch – 9:54 PM ET 04/21/2015

    Teva Pharmaceutical Industries (TEVA)' $40 billion offer for Mylan has much to recommend it. That doesn't mean it will happen at an acceptable price. For Teva, the logic for the cash-and-stock bid is straightforward.

Page:

Today's and Upcoming Events

  • Jul
    15

    ABT to announce Q2 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Apr
    24

    Shareholders Meeting

  • Apr
    22

    ABT Earnings Conference Call at 9:00 AM Listen

  • Apr
    13

    ABT ex-Dividend for $0.24 on 4/13/2015

    • Announce Date: 2/20/2015
    • Record Date: 4/15/2015
    • Pay Date: 5/15/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.